Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus usual care anticoagulation for cardioversion in non-valvular atrial fibrillation
2014-001231-36Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of apixaban in Atrial fibrillation (AFib) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Stroke. Started Jul 2014; status: completed.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2014-001231-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001231-36.